MediWound Ltd.

MDWD Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.85 0.36 −2.95%
Market cap
$157.6M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.05
Beneish M
−3.69
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 17.23 0.00 0.00 0.00
Piotroski F-Score
5 2 2 4 4 2 7 4 5 4
P/S ratio
12.38 8.77 5.43 2.50 2.71 4.63 2.65 32.38 42.56 73.69
Altman Z-Score
(1.05) (1.57) (2.01) (2.88) (9.36) (3.09) (0.45) (2.00) (2.28) (2.92)
Altman Z″-Score (non-manufacturers)
(6.94) (7.81) (6.05) (7.35) (27.13) (11.97) (4.65) (7.30) (5.99) (8.09)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 11.31 0.00 0.00 0.00
Beneish M-Score
(3.69) (3.23) (0.95) (1.21) (3.85) (2.68) 4.34 (0.82) (2.94) —
P/Operating CF
(69.64) (108.30) (38.77) 33.14 (28.77) (30.36) (36.72) (54.87) (24.12) (27.14)
P/B ratio
4.81 5.69 3.21 6.07 0.00 13.85 5.56 12.27 11.04 14.78
Price to Tangible BV
4.82 5.71 3.23 6.20 0.00 14.58 5.72 12.99 11.82 16.41
EV/Sales
9.30 6.66 3.31 1.24 2.27 3.66 1.74 25.47 28.17 54.51
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 9.82 0.00 0.00 0.00
EV/Operating CF
(9.79) (9.89) (5.91) (2.77) (6.04) (11.56) 6.68 (7.13) (4.27) (5.16)
EV/FCF
(7.28) (6.76) (3.64) (2.64) (5.70) (10.14) 7.43 (6.81) (4.00) (4.91)
Quick Ratio
2.17 1.86 2.58 3.64 1.28 3.00 3.28 6.34 7.30 6.09
Current Ratio
2.33 1.97 2.74 3.80 1.39 3.17 3.43 6.68 7.64 6.25
Net Debt/EBITDA
2.27 2.41 2.98 4.79 1.11 2.79 (5.22) 6.99 2.75 1.53
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.21 0.29 0.32 0.76 0.94 0.61 0.84 0.09 0.06 0.04
Operating CF/Net income
0.68 0.45 1.56 0.61 0.66 0.75 1.67 11.50 0.74 0.87
Capex/Depreciation
(2.96) (4.23) (4.96) (0.44) (0.39) (0.85) (0.69) (0.93) (1.90) (1.19)
Interest Coverage
(10.27) (1.51) (8.08) (0.72) (4.85) (6.91) 1.51 (1.87) (10.93) (22.49)
ROE
(63.86%) (96.33%) (31.60%) (619.05%) (1,007.51%) (81.96%) 41.05% (11.37%) (254.73%) (120.90%)
ROA
(29.90%) (43.19%) (11.53%) (56.19%) (53.34%) (25.67%) 13.06% (2.66%) (55.44%) (42.78%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(45.14%) (76.03%) (16.46%) (54.22%) (201.98%) (44.73%) 17.98% (3.54%) (58.27%) (64.00%)
Average Days of Receivables
58.78 113.89 100.42 137.51 41.56 54.16 52.32 794.18 521.32 641.68
Research and Development Expense of Revenue
84.44% 43.90% 39.96% 38.42% 43.16% 35.37% 15.63% 119.73% 218.83% 453.66%
Selling, General and Administrative Expense of Revenue
83.81% 64.97% 62.14% 40.18% 40.97% 39.92% 29.27% 234.84% 366.31% 801.48%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.02 0.01 0.01 0.01 0.01 0.02
Share Based Compensation of Revenue
18.33% 15.52% 10.38% 7.34% 7.04% 6.07% 3.88% 18.97% 54.61% 203.53%
Graham Net Nets
0.08 0.06 0.15 0.10 (0.15) 0.02 0.12 0.06 0.07 0.05
Graham Number
0.00 0.00 0.00 0.00 9.53 0.00 10.52 0.00 0.00 0.00
Earnings Yield
(11.38%) (17.25%) (6.84%) (28.89%) (20.76%) (8.92%) 5.80% (0.98%) (21.53%) (16.38%)
Free Cash Flow Yield
(10.32%) (11.25%) (16.74%) (18.83%) (14.69%) (7.80%) 8.85% (11.55%) (16.56%) (15.06%)
Revenue per Share
1.49 2.03 2.07 5.31 6.11 5.60 8.18 0.88 0.75 0.50
Operating CF per Share
(1.42) (1.37) (1.16) (2.38) (2.29) (1.77) 2.13 (3.14) (4.93) (5.26)
Capex per Share
(0.48) (0.63) (0.72) (0.11) (0.13) (0.24) (0.20) (0.14) (0.32) (0.22)
Free Cash Flow per Share
(1.90) (2.00) (1.88) (2.49) (2.42) (2.01) 1.93 (3.27) (5.26) (5.49)
Cash per Share
4.67 4.33 4.63 6.80 2.84 5.55 7.58 6.10 10.81 9.61
Shareholders Equity per Share
3.84 3.13 3.51 2.19 (1.18) 1.87 3.91 2.32 2.88 2.49
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.84 3.13 3.51 2.19 (1.18) 1.87 3.91 2.32 2.88 2.49
Free Cash Flow
(21.63) (19.90) (16.93) (12.44) (9.40) (7.82) 7.50 (12.69) (17.53) (17.15)
Working Capital
34.26 25.62 31.57 33.78 4.23 17.93 25.26 27.82 36.09 28.23
Capital Expenditures
(5.50) (6.27) (6.46) (0.55) (0.49) (0.92) (0.79) (0.53) (1.07) (0.70)
Net Current Asset Value
17.34 9.82 14.83 6.74 (9.37) 2.40 10.21 6.41 7.01 5.62
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 12.33 0.00 0.00 0.00
Capex to Sales
0.32 0.31 0.35 0.02 0.02 0.04 0.02 0.16 0.43 0.45
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 18.76 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.10 0.10 0.14 0.54 0.50 0.41 0.50 0.29 0.29 0.46
Cash ROIC
(22.35%) (26.77%) (23.09%) (27.76%) (145.50%) (27.09%) 16.80% (38.91%) (38.37%) (45.36%)
Accounts Receivable Turnover
3.75 3.53 2.47 4.18 8.01 5.59 5.32 0.62 0.79 0.55
Accounts Payable Turnover
2.12 3.25 2.70 2.58 3.90 4.03 3.49 0.70 0.48 0.97
Inventory Turnover
4.04 6.35 6.28 8.43 11.62 9.50 7.20 1.17 1.16 1.69
Average Days of Payables
203.69 109.60 133.55 154.86 114.26 76.81 125.28 474.60 751.97 561.54
Days of Inventory on Hand
109.01 55.87 68.76 53.75 29.22 35.43 49.69 293.68 436.24 142.75
Average Receivables
4.52 5.73 7.56 6.34 2.97 3.89 5.98 5.48 3.15 2.83
Average Payables
6.46 5.40 5.59 5.17 3.84 3.53 3.39 2.98 3.29 2.22
Average Inventory
3.39 2.77 2.40 1.58 1.29 1.50 1.65 1.78 1.37 1.28
Average Assets
79.88 69.98 58.24 34.88 25.41 35.83 37.93 39.71 39.95 44.14
Average Common Equity
37.39 31.37 21.25 3.17 1.35 11.22 12.07 9.30 8.70 15.62

Fold the line items

Columns are period end dates